Rationale And Objectives: Carbamazepine has shown reasonable antimanic properties, but its use has been limited because of enzyme-inducing effects. The keto-derivative oxcarbazepine (OXC) is very similar to carbamazepine, however, the metabolic pathway is different. OXC is not metabolized to the 10, 11-epoxide, which seems to be responsible for several undesirable side-effects of carbamazepine and furthermore OXC has less enzyme-inducing properties.
Methods: In this non-random open label study, patients were treated with OXC for 14 days, crossed over to no OXC for 7 days, and then crossed back over to OXC for the remaining 14 days. OXC was titrated to a final dose in a range of 900-2100 mg due to individual response. Treatment success was defined as a reduction of the original Young Mania Rating Scale (YMRS) score of more than 50% at the end of study period.
Results: Four of the 12 included patients (33%) met defined response criteria at the end of study period. Fifty percentage of the patients had to be prematurely excluded from the trial. The mean YMRS scores of the on-periods were obviously different from the off-period. Forty-two percentage of the patients experienced side-effects leading to premature discontinuation in two of 12 patients.
Conclusion: Antimanic activity of OXC was demonstrated in this pilot study only for patients with mild or moderate manic symptoms. Further studies are encouraged to clarify OXC's role as mood-stabilizer and assess whether it has a profile similar to that of carbamazepine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1034/j.1399-5618.2002.02228.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy and safety of gabapentin, pregabalin, oxcarbazepine, and duloxetine in diabetic peripheral neuropathy: A network meta-analysis.
Perspect Clin Res
July 2024
Department of Pharmacology, Smt.NHL MMC, Ahmedabad, Gujarat, India.
Purpose: To conduct a network meta-analysis comparing the safety and efficacy of gabapentin (GBP), pregabalin (PGB), oxcarbazepine (OXC), and duloxetine (DLX) in treating diabetic peripheral neuropathy (DPN).
Materials And Methods: The study's eligibility criteria includee randomized controlled trials (RCTs) with a focus on DPN patients receiving GBP, PGB, DLX, or OXC versus placebo. Noncompliant trials with incomplete information and observational studies were excluded.
The Effect of Grouper Bone Nano-Calcium (GBN) and Medium-Chain Triglyceride (MCT) Supplementation on the Ovariectomized Rats.
J Nutr Metab
November 2024
Micro-CT Laboratory, Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, Bandung 40132, Indonesia.
Article Synopsis
- - The research aimed to determine the effects of replacing synthetic calcium carbonate (CaCO) with grouper bone nano-calcium (GBN) and using medium-chain triglycerides (MCT) instead of long-chain triglycerides (LCT) in the diets of ovariectomized rats over eight weeks.
- - Four groups of twenty rats were studied, with results showing that those fed with GBN exhibited better bone density and strength compared to the synthetic CaCO group, while the calcium-deficient group performed poorly.
- - The study concluded that GBN was an effective alternative to synthetic calcium and that MCT performed similarly to LCT, though it did not prove superior.
Molecular Nanoinformatics Approach Assessing the Coating Oxcarbazepine (OXC) Drug on Silver Nanoparticles.
ACS Omega
November 2024
Christus University Center, 60160-230 Fortaleza, CE, Brazil.
Silver nanoparticles (AgNP) have gained significant attention due to their unique pharmacological properties. These nanoparticles have been found to possess antimicrobial, anti-inflammatory, and antioxidant activities, making them promising candidates for various medical applications. The coating characteristics of oxcarbazepine (OXC), a drug used in epilepsy treatment, on the AgNP icosahedral clusters were investigated using molecular dynamics (MD) simulations and noncovalent interactions (NCI) and Independent Gradient Model (IGM) analysis.
View Article and Find Full Text PDFOptimizing antigen preparation for oxalyl-CoA decarboxylase enzyme diagnostic kit and ELISA system cutoff determination.
Urolithiasis
October 2024
Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
The prevalence of kidney stone disease is increasing globally, with calcium oxalate stones being the most common type. Oxalyl-CoA decarboxylase (OXC), an enzyme produced by the gut bacterium Oxalobacter formigenes, plays a crucial role in oxalate metabolism. Deficiencies in OXC activity can lead to the accumulation of oxalate, contributing to kidney stone formation.
View Article and Find Full Text PDFSecondary products and molecular mechanism of calcium oxalate degradation by the strain Azospirillum sp. OX-1.
Sci Rep
October 2024
College of Life Sciences, College of Marine Science and Engineering, Nanjing Normal University, Nanjing, 210023, China.
Article Synopsis
- The oxalate-carbonate pathway (OCP) involves converting soil oxalate into stable carbonates, but a better understanding of the process is essential for effective management.
- A bacteria strain, Azospirillum sp. OX-1, was studied for its ability to degrade calcium oxalate, revealing that it not only transforms it into calcium carbonate but also produces methane as a byproduct.
- Proteomic analysis indicated that OX-1 utilizes specific enzymes for oxalate degradation and that methane production may be more common in other soil bacteria, prompting a reassessment of OCP's effectiveness in carbon reduction strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!